ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Chugai Pharmaceutical Co., Ltd.

Business Summary

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2022 JPYUSD
Revenue1,259.94B9,579.32M
Gross Profit783,062M5,953.59M
Operating income533,942M4,059.54M
Income before tax531,166M4,038.43M
Net income374,429M2,846.77M
EBITDA565,376M4,298.53M
Diluted EPS227.561.73
Dividends Per Share780.59
Total Assets1,869.75B14,170.73M
Total liabilities445,371M3,375.42M
Total equity1,424.38B10,795.30M
Operating cash flow244,335M1,857.67M
Currency in JPYCurrency in USD

Historical Data

 Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022
Revenue 579,787M 686,184M 786,945M 999,758M 1,259.94B
Gross Profit 316,025M 419,922M 511,775M 660,268M 783,062M
Operating income 129,225M 214,513M 306,882M 433,738M 533,942M
Income before tax 121,449M 207,893M 298,188M 419,385M 531,166M
Net income 92,488M 157,560M 214,733M 302,995M 374,429M
EBITDA 145,803M 240,914M 337,358M 464,606M 565,376M
Diluted EPS 56.26 95.80 130.53 184.16 227.56
Dividends Per Share 28.66 46.66 54.99 76 78
Total Assets 919,548M 1,058.91B 1,235.49B 1,538.69B 1,869.75B
Total liabilities 163,020M 204,929M 255,494M 350,677M 445,371M
Total equity 755,865M 853,985M 980,003M 1,188.01B 1,424.38B
Operating cash flow 119,269M 206,811M 205,101M 279,711M 244,335M
 Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022
Revenue 5,249.65M 6,294.64M 7,370.57M 9,099.19M 9,579.32M
Gross Profit 2,861.43M 3,852.11M 4,793.31M 6,009.36M 5,953.59M
Operating income 1,170.06M 1,967.81M 2,874.27M 3,947.62M 4,059.54M
Income before tax 1,099.65M 1,907.08M 2,792.84M 3,816.98M 4,038.43M
Net income 837.42M 1,445.36M 2,011.20M 2,757.67M 2,846.77M
EBITDA 1,320.16M 2,210.00M 3,159.71M 4,228.56M 4,298.53M
Diluted EPS 0.50 0.87 1.22 1.67 1.73
Dividends Per Share 0.25 0.42 0.51 0.69 0.59
Total Assets 8,381.24M 9,743.86M 11,966.66M 13,361.93M 14,170.73M
Total liabilities 1,485.84M 1,885.70M 2,474.63M 3,045.26M 3,375.42M
Total equity 6,889.34M 7,858.15M 9,492.01M 10,316.67M 10,795.30M
Operating cash flow 1,079.91M 1,897.16M 1,920.98M 2,545.76M 1,857.67M

Valuation Measures

Dec 2022
PER14.79
ROA21.97%
ROE28.66%
Operating margin42.37%
Profit margin29.71%

Management

  • President, CEO & Representative Director: Osamu Okuda
  • CFO, Manager-Information Technology & Accounting: Itagaki Toshiaki
  • Executive Officer, GM-Research & Development: Junichi Nezu
  • Senior Executive Officer & Head-Research: Hisafumi Okabe
  • Executive Officer: Toshihiko Komori

Shareholders

  • Roche Holding AG (59.8%)
  • Nomura Asset Management Co., Ltd. (3.0%)
  • Chugai Pharmaceutical Co., Ltd. (2.0%)
  • Wellington Management Co. LLP (1.9%)
  • Nikko Asset Management Co., Ltd. (1.4%)
  • Daiwa Asset Management Co. Ltd. (1.4%)
  • The Vanguard Group, Inc. (1.3%)
  • Harding Loevner LP (0.9%)
  • BlackRock Fund Advisors (0.8%)
  • Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.7%)

Contact Details

  • Website:http://www.chugai-pharm.co.jp
  • Address: Nihonbashi Mitsui Tower, 15/F, 2-1-1 Nihonbashi-Muromachi, Tokyo, 103-8324, Japan
  • Phone: +81.3.3281.6611

Related Companies

  • Chugai Pharmaceutical Co. Ltd. /Bonviva Drug Business/
  • Chugai Pharma Europe Logistics SAS
  • Chugai Pharma Germany GmbH
  • Chugai Distribution Co., Ltd.
  • Medical Culture YK
  • Chugai Business Support Co., Ltd.
  • Chugai Clinical Research Center Co., Ltd.
  • Chugai Pharma Technology Taizhou Co., Ltd.
  • Chugai Pharmaceutical Restricted Stock Compensation Plan
  • Chugai Pharma Consulting (Shanghai) Co., Ltd.
  • Chugai Pharma R&D Taiwan Ltd.
  • Chugai Pharma China Co., Ltd.
  • Chugai Pharma Science (Beijing) Co., Ltd.
  • Chugai Pharma Taiwan Ltd.
  • Chugai Pharmabody Research Pte Ltd.
  • Pharmalogicals Research Pte Ltd.
  • Forerunner Pharma Research Co., Ltd.
  • Chugai Research Institute for Medical Science, Inc.
  • Chugai Pharma Manufacturing Co., Ltd.
  • Chugai Pharmaceutical Employee Stock Ownership Plan
  • Chugai Pharma U.K. Ltd.
  • Chugai Pharma France SAS
  • Chugai Biopharmaceuticals, Inc.
  • Chugai Pharma USA LLC
  • Nippon Roche KK

Competitors

  • Horizon Therapeutics Public Limited Company
  • Regeneron Pharmaceuticals, Inc.
  • Springworks Therapeutics, Inc.
  • Genelux Corp.
  • Celldex Therapeutics, Inc.
  • Apellis Pharmaceuticals, Inc.
  • Cara Therapeutics Inc
  • Immunic, Inc.
  • Equillium, Inc.
  • UBI Pharma, Inc.
  • Context Therapeutics, Inc.
  • Nuvalent, Inc. Class A
  • PanGen Biotech, Inc.
  • ACELYRIN, INC.
  • Acumen Pharmaceuticals, Inc.
  • Ardelyx, Inc.
  • ProMIS Neurosciences Inc.
Last Updated on 22 Sep, 2023

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more